DBV Technologies SA (NASDAQ:DBVT)

9.46
Delayed Data
As of Sep 20
 -0.17 / -1.77%
Today’s Change
3.60
Today|||52-Week Range
25.77
+47.35%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$685.6M

Company Description

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Contact Information

DBV Technologies SA
177-181, avenue Pierre Brossolette
Montrouge Ile-de-france 92120
P:(315) 542-7878
Investor Relations:
(212) 271-0740

Employees

Shareholders

Mutual fund holders9.58%
Other institutional34.28%
Individual stakeholders--

Top Executives

Daniel TasséChief Executive Officer & Executive Director
Bertrand DupontChief Technology Officer
Hugh A. SampsonChief Scientific Officer
Pharis MohideenChief Medical Officer
Pascale EhouarnChief Engineering, Manufacturing & Supply Officer